Home » Orencia Becomes First Biologic Available as Injection or Infusion for Rheumatoid Arthritis
Orencia Becomes First Biologic Available as Injection or Infusion for Rheumatoid Arthritis
Bristol-Myers Squibb received FDA approval to market a new formulation of Orencia (abatacept) for the treatment of adults with moderate to severe rheumatoid arthritis.
About
About
Upcoming Events
-
07May
-
14May
-
30May